27 months vs. 5.87 months, P = 0.002), in patients PCI-32765 chemical structure without ascites than with ascites (8.97 months vs. 5.00 months, P = 0.049), and in patients without tumor thrombus than with tumor thrombus (11.37 months vs. 5.00 months, P = 0.005). Multivariate analyses showed that PFS time was independently correlated with age (P = 0.047) and OS time was independently
correlated with HBsAg positivity (P = 0.037), AFP level (P = 0.015), and tumor size (P = 0.003). Table 2 Univariate analyses of the relationships between clinicopathologic factors and survival Parameters N PFS OS Months χ 2 P Months χ 2 P Gender Male 55 4.433 7.400 Female 10 6.200 0.609 0.435 10.200 0.340 0.560 Age ≤50 22 4.000 5.867 >50 43 5.833 3.934 0.047 8.067 0.113 0.736 HBsAg Positive 55 4.433 6.467 Negative 10 5.833 0.516 0.472 8.800 3.608 0.057 AFP(IU/ml) ≤400 31 7.000 11.133 >400 34 4.233 Baf-A1 3.016 0.082 find more 5.200 5.236 0.022 Tumor number Single 18 5.600 8.967 >1 47 4.967 0.168 0.682 5.867 0.981 0.322 Tumor size(cm) ≤5 12 7.300 29.267 >5 53 4.367 3.792 0.051 5.867 9.834 0.002 Differentiation High 17 6.200 5.233 Middle 33 4.367 8.967 Low 15 4.000 3.630 0.163 5.667 3.097 0.213 Child-Pugh A 59 5.600 8.067 B 6 4.967 0.599 0.439
3.600 1.980 0.159 BCLC B 7 5.633 10.500 C 58 4.433 3.527 0.060 7.400 0.274 0.600 Hepatic cirrhosis Yes 34 4.967 6.533 No 31 4.433 0.002 0.965 8.967 0.194 0.659 Ascites Yes 14 4.367 5.000 No 51 5.600 Dichloromethane dehalogenase 2.706 0.100 8.967 3.887 0.049 Tumor thrombus Yes 28 3.000 5.000 No 37 5.833 2.800 0.094 11.367 8.067 0.005 Extrahepatic metastasis Yes 41 4.367 6.467 No 24 5.600 0.878 0.349 8.967 0.017 0.897 PFS, progression-free survival; OS, overall survival; HbsAg, hepatitis B surface antigen; AFP, serum alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer stage. VEGFR-2, PDGFR-β, c-MET
Relationships between expression of VEGFR-2, PDGFR-β, and c-MET and prognosis in patients who took sorafenib We used the Kaplan-Meier method and log-rank test to analyze the association between the expression of VEGFR-2, PDGFR-β, c-Met and prognosis. Among the 65 patients who took sorafenib, there was no significant difference between patients with high and low expression of VEGFR-2 in PFS time (P = 0.532) or OS time (P = 0.473). There was no significant difference between patients with high and low expression of PDGFR-β in PFS time (P = 0.246), but the median OS time was shorter in patients with high expression of PDGFR-β than low expression of PDGFR-β (5.87 months vs.